Skip to content

Myostatin Propeptide

The N-terminal propeptide domain of myostatin that remains non-covalently bound to mature myostatin in latent extracellular complexes — characterized by Hill, Lee, and colleagues (JBC 2002, Mol Endocrinol 2003) as one of the principal endogenous inhibitors of myostatin signaling, alongside follistatin and the GASP-1/GASP-2 follistatin-related proteins. Studied as a research-tier myostatin antagonism strategy in muscular dystrophy, sarcopenia, and muscle-wasting models.

DPreliminaryLimited Data
Last updated 15 citations
TL;DR

Myostatin does not float around the body ready to act. It is secreted pre-packaged with its own N-terminal propeptide wrapped around it, inert until a BMP-1/tolloid protease cuts the wrapper off — and more than 70% of the myostatin in serum is sitting in that latent state at any moment. Hand animals extra propeptide and you keep more myostatin bottled up: transgenic mice expressing it gained muscle mass comparable to full myostatin knockouts. That is where the propeptide story stops. No propeptide construct has ever been given to a human, and the clinical myostatin-blockade field went to antibodies instead — one of which, apitegromab, became the first approved myostatin drug in September 2026. Athletes should note the propeptide is not an untested grey area to WADA: it is named, by name, in the Prohibited List.

What is Myostatin Propeptide?

Myostatin propeptide is the N-terminal regulatory domain of myostatin (GDF-8) — the segment of the myostatin precursor protein that is cleaved from the mature signaling C-terminal domain during proteolytic processing but remains non-covalently associated with mature myostatin in the secreted latent extracellular complex. The propeptide acts as an endogenous inhibitor of myostatin signaling: when bound to mature myostatin, it prevents myostatin from binding to its activin receptors (ActRIIA/ActRIIB) and activating the Smad2/3 pathway that drives myostatin's muscle-mass-limiting effects. Myostatin must be released from the latent propeptide complex (typically via metalloprotease cleavage of the propeptide by BMP-1, tolloid family enzymes, or other proteases) to become biologically active. The Hill et al. 2002 Journal of Biological Chemistry paper (PMID 12194980) is the foundational characterization paper, identifying the myostatin propeptide and the follistatin-related gene (FLRG, now FSTL3) as the principal inhibitory binding proteins of myostatin in normal serum, and reporting that a majority — more than 70% — of the myostatin circulating in normal serum is held in the latent propeptide-bound form. The follow-up Hill et al. 2003 Molecular Endocrinology paper (PMID 12595574) extended the work to growth and differentiation factor-associated serum protein-1 (GASP-1) — a novel protein with protease inhibitor and follistatin domains — and consolidated the broader latent-complex-and-binding-protein framework for endogenous myostatin regulation. The Lee and McPherron 2001 PNAS paper (PMID 11459935) is the key experiment rather than a review: transgenic mice overexpressing the propeptide gained muscle mass comparable to myostatin-null animals. Myostatin propeptide has been studied as a research-tier myostatin antagonism strategy — administering recombinant myostatin propeptide produces myostatin sequestration and downstream muscle-mass increase in animal models of muscular dystrophy (Duchenne mouse models, Becker muscular dystrophy contexts), sarcopenia, and other muscle-wasting conditions. The propeptide itself has never been given to a human, and the clinical myostatin-antagonism strategies that did reach patients are antibody-based (apitegromab, the SRK-015 selective pro-myostatin antibody from Scholar Rock — Phase 3 SAPPHIRE read out in non-ambulatory SMA patients (Crawford, Servais, Mercuri and colleagues, Lancet Neurology September 2025, PMID 40818473)) and decoy-receptor-based (ACE-031 historical, bimagrumab, GYM329) rather than propeptide-based. Myostatin propeptide remains research-tier and is sold through some research-chemical sources for laboratory use, but is not FDA-approved or in active commercial clinical development.

What Myostatin Propeptide Is Investigated For

Myostatin propeptide is a research-tier myostatin antagonism topic, not a clinical therapy. The N-terminal propeptide domain of myostatin acts as an endogenous inhibitor by sequestering mature myostatin in latent extracellular complexes — preventing receptor binding and downstream Smad2/3 signaling that drives myostatin's muscle-mass-limiting effects. The Hill et al. 2002 JBC and 2003 Mol Endocrinol papers (PMIDs 12194980, 12595574) established the propeptide-and-latent-complex framework and identified the propeptide alongside FSTL3/GASP-1 as the principal endogenous myostatin inhibitors. Recombinant myostatin propeptide has been studied as a myostatin-antagonism strategy in animal models of muscular dystrophy, sarcopenia, and muscle wasting — with documented muscle-mass increases through myostatin sequestration. The clinical translation has not advanced to FDA-approved therapy because the dominant clinical myostatin-antagonism strategies are antibody-based (apitegromab/SRK-015 from Scholar Rock — Phase 3 SAPPHIRE now read out in non-ambulatory SMA per Crawford 2025 Lancet Neurol; the same antibody has moved into Phase 2 for lean-mass preservation during tirzepatide-induced weight loss per Pratley 2026 Nat Med, a major new GLP-1-adjacent indication; plus bimagrumab, now an Eli Lilly asset in active Phase 2 trials and the subject of the Shao 2026 DOM obesity meta-analysis, GYM329, and others) and decoy-receptor-based (ACE-031 historical, ActRIIB-Fc fusions) rather than propeptide-based. It is worth being careful about why the propeptide was passed over, because the usual explanation — that antibodies were simply the more tractable format — is an assumption rather than a documented decision, and the antibody and decoy-receptor arms are precisely the ones that failed in humans. Domagrozumab was terminated in Duchenne for lack of efficacy, taldefgrobep was stopped in Duchenne after a pre-planned futility analysis, ACE-031 was halted on preliminary safety data, and MYO-029 missed its endpoint in muscular dystrophy. The propeptide was never tested against any of them, so no head-to-head evidence exists in either direction; what can be said is that it was not developed, not that it was tried and found wanting. Anyone considering myostatin propeptide for fitness or muscle-mass goals should engage with the honest framing — research-tier biology, no FDA approval, dominant clinical myostatin-antagonism strategies are antibody-based not propeptide-based, no validated consumer-research-channel use case.

Endogenous regulator of myostatin signaling — propeptide-and-latent-complex framework characterized by Hill et al. 2002-2003
Strong90%
Research-tier myostatin antagonism strategy with documented muscle-mass effects in animal models
Preliminary30%
Mechanistically distinct from antibody-based and decoy-receptor-based myostatin antagonism
Moderate70%
The broader myostatin-antagonism drug class has extended into GLP-1-adjacent lean-mass preservation — apitegromab/SRK-015 Phase 2 with tirzepatide read out in July 2026 (Pratley 2026 Nat Med) alongside the 2025 Phase 3 SAPPHIRE SMA readout
Moderate70%
Conceptual reference for understanding myostatin biology and the broader TGF-β-superfamily latent-complex regulatory architecture
Strong90%

How It Works

Myostatin propeptide is a piece of the myostatin protein itself — the N-terminal segment that gets cut off when myostatin is processed. Even after cutting, the propeptide stays stuck to mature myostatin and acts like a cap that prevents myostatin from binding its receptors and limiting muscle growth. So the propeptide is your body's own way of keeping myostatin inactive until it's needed. Researchers can give animals extra recombinant propeptide to keep more myostatin sequestered and let muscles grow more. It's interesting biology, but the actual drug development for muscle-wasting diseases is using antibodies (like apitegromab from Scholar Rock for SMA) rather than the propeptide approach, because antibodies are easier to manufacture as drugs.

Myostatin (GDF-8) is biosynthesized as a 375-residue precursor protein consisting of a signal peptide, a propeptide (N-terminal regulatory domain), and the mature signaling C-terminal domain. During biosynthesis, the precursor undergoes proteolytic processing — first removal of the signal peptide, then furin-protease cleavage at the RXRR site separating the propeptide from the mature C-terminal signaling domain. The cleaved fragments do not dissociate; the propeptide remains non-covalently bound to mature myostatin, forming the secreted latent extracellular complex. In the latent complex, myostatin cannot bind its activin receptors (ActRIIA, ActRIIB) and cannot activate the downstream Smad2/3 signaling pathway that drives myostatin's muscle-mass-limiting effects. For myostatin to become biologically active, the propeptide must be released. This activation step is mediated by metalloprotease cleavage of the propeptide — BMP-1, tolloid-like proteases (mTLD, mTLL-1, mTLL-2), and potentially other proteases cleave the propeptide and release mature myostatin from the latent complex. The activation step is regulated, providing a control point for myostatin signaling separate from the synthesis-and-secretion step. The Hill et al. 2002 JBC paper (PMID 12194980) characterized the propeptide-and-latent-complex framework in detail, identifying the myostatin propeptide alongside FSTL3 (follistatin-like 3, also called FLRG) as the principal inhibitory binding proteins of myostatin in normal mouse and human serum, with more than 70% of serum myostatin bound to its propeptide. The follow-up Hill et al. 2003 Mol Endocrinol paper (PMID 12595574) extended the work to growth and differentiation factor-associated serum protein-1 (GASP-1) — a novel protein with protease inhibitor and follistatin domains that also binds mature myostatin in serum. Lee and McPherron 2001 (PMID 11459935) supplied the functional proof in vivo, with propeptide-transgenic mice reaching muscle mass comparable to myostatin knockouts. Recombinant myostatin propeptide can be used as a myostatin-antagonism research tool. Administering recombinant propeptide produces sequestration of circulating myostatin, reducing the active mature myostatin available for receptor binding and downstream signaling. In animal models of muscular dystrophy (mdx mice for Duchenne, dystrophin-deficient models), the propeptide approach produces measurable muscle-mass increase and improved muscle function. Similar effects have been documented in sarcopenia and other muscle-wasting models. The translational pathway has not advanced to FDA-approved therapy because the dominant clinical myostatin-antagonism drug development strategies are antibody-based — apitegromab (SRK-015, Scholar Rock) is a pro-myostatin-selective antibody with Phase 3 SAPPHIRE having read out in non-ambulatory SMA patients (Crawford, Servais, Mercuri and colleagues, Lancet Neurol Sept 2025, PMID 40818473) and a Phase 2 program for lean-mass preservation during tirzepatide-induced weight loss (Pratley, Denham, Trivedi and colleagues, Nat Med July 2026, PMID 42260100) that materially reframes the clinical myostatin-antagonism landscape from primarily muscular dystrophy and SMA toward a far larger GLP-1-adjacent obesity-therapy adjunct market; bimagrumab, an ActRIIA/ActRIIB-targeting antibody originally developed at Novartis and now an Eli Lilly asset (LY3985863), is in active Phase 2 development in combination with tirzepatide and in heart failure with preserved ejection fraction; GYM329 and other antibodies are in earlier development. Decoy-receptor-based approaches (ACE-031 historically, ActRIIB-Fc fusion proteins) provide an alternative class. The propeptide approach has remained research-tier without commercial clinical development.

Evidence Snapshot

Overall Confidence35%

Human Clinical Evidence

None.

Animal / Preclinical

Substantial. Recombinant myostatin propeptide produces muscle-mass increase in dystrophin-deficient and other muscle-wasting mouse models. Hill et al. 2002-2003 papers establish the regulatory framework.

Mechanistic Rationale

Strong. The propeptide-and-latent-complex regulatory architecture is well-characterized at the molecular level. The translational gap is at the drug-development-and-formulation level, not the mechanism level.

Research Gaps & Open Questions

What the current literature has not yet settled about Myostatin Propeptide:

  • 01Whether myostatin propeptide approach has any commercial-development advantages over antibody-based and decoy-receptor-based myostatin antagonism that could justify revisiting the propeptide pathway
  • 02Long-term safety profile of chronic myostatin propeptide administration in humans
  • 03Whether selective myostatin propeptide pharmacology produces a different tissue-specific effect profile than broader-spectrum myostatin antagonism
  • 04Whether the class-wide bone signal applies to the propeptide. The approved antibody apitegromab carries a fracture warning and produced femoral-head lesions at every dose in rat toxicology with no no-effect dose identified; no equivalent skeletal assessment has ever been run on a propeptide construct.
  • 05Whether a minimal peptide can substitute for the whole propeptide. A 23-amino-acid fragment of the mouse prodomain retains myostatin inhibition, and a 2026 paper reported all-D tripeptide prodrug mimetics of that fragment with over 24 hours of proteolytic stability that increased soleus mass and grip strength in mice — the first serious attempt to make the propeptide concept druggable rather than abandon it.
  • 06Whether propeptide-mediated myostatin blockade shares the metabolic effects seen with receptor-level blockade. Propeptide-transgenic mice were protected from diet-induced obesity and insulin resistance, which is the same territory the GLP-1-adjacent antibody programmes are now entering, but no one has followed it up.

Forms & Administration

Recombinant myostatin propeptide is sold as a research reagent through some peptide and recombinant-protein suppliers for laboratory use. There is no FDA-approved myostatin-propeptide drug or clinical formulation.

Common Questions

What is the myostatin propeptide?

The myostatin propeptide is the N-terminal domain of the myostatin precursor protein. During biosynthesis, myostatin is produced as a longer precursor that is cleaved into a propeptide (N-terminal) and the mature signaling domain (C-terminal). The propeptide remains non-covalently bound to mature myostatin in the secreted latent complex — and as long as the propeptide is bound, myostatin cannot bind its activin receptors and activate downstream signaling. The propeptide must be released (typically by metalloprotease cleavage by BMP-1, tolloid family enzymes, or other proteases) for myostatin to become biologically active. The Hill et al. 2002 JBC paper (PMID 12194980) is the foundational characterization of this latent-complex framework and identified the propeptide alongside follistatin-related proteins as the principal endogenous inhibitors of myostatin in serum.

Is myostatin propeptide used as a drug?

No FDA-approved myostatin-propeptide drug exists. The molecule is research-tier — administering recombinant myostatin propeptide in animal models produces myostatin sequestration and muscle-mass increase, but the clinical translation pathway has not advanced. The dominant myostatin-antagonism drug development strategies in development are antibody-based (apitegromab/SRK-015 from Scholar Rock, approved for spinal muscular atrophy in September 2026 on the strength of the Phase 3 SAPPHIRE trial; bimagrumab, now an Eli Lilly asset in active Phase 2 trials; GYM329; and others) and decoy-receptor-based (ACE-031 historically, ActRIIB-Fc fusion proteins). Why the propeptide was never developed clinically is not documented anywhere in the literature — the commonly repeated explanation about manufacturing and pharmacokinetics is plausible but unsourced, and no trial has ever compared the two formats. Myostatin propeptide is sold through some research-chemical sources for laboratory use but is not FDA-approved or in active commercial clinical development.

How is myostatin propeptide different from follistatin or GASP-1?

All three are endogenous inhibitors of myostatin, but they bind different parts of myostatin biology and have different broader pharmacology. The myostatin propeptide is myostatin's own N-terminal regulatory domain — it binds mature myostatin in the latent complex specifically. Follistatin is a separate protein that binds and neutralizes multiple TGF-β superfamily ligands including myostatin, activin, and others — broader specificity than the propeptide. GASP-1 (growth and differentiation factor-associated serum protein 1) is a separate protein again — encoded by WFIKKN2 on chromosome 17q21.33, carrying both protease-inhibitor and follistatin domains, and binding mature myostatin in serum (Hill 2003 Mol Endocrinol PMID 12595574). It is frequently and incorrectly equated with FSTL3/FLRG, which is a different gene on a different chromosome (19p13.3). The three proteins together make up the principal endogenous regulatory architecture of myostatin signaling. The propeptide is myostatin-specific by virtue of being myostatin's own regulatory domain; follistatin and GASP-1 are broader-specificity inhibitors that affect myostatin alongside other TGF-β superfamily members.

Should I use myostatin propeptide for muscle building?

There is no validated consumer-research-channel use case. Myostatin propeptide is research-tier with no FDA approval, no validated dosing protocol, no human safety data, and no clinical efficacy data. The dominant clinical myostatin-antagonism strategies are antibody-based (apitegromab/SRK-015 — Phase 3 SAPPHIRE read out in non-ambulatory SMA in 2025 and Phase 2 for lean-mass preservation with tirzepatide read out in 2026) and decoy-receptor-based — none in current FDA-approved use for fitness or muscle-mass goals. For body composition and muscle development, the validated foundations remain progressive-overload resistance training, adequate protein intake (~1.6-2.2 g/kg/day for fitness goals), sleep, and individualized clinical care for diagnosed conditions. Research-channel myostatin propeptide is not the appropriate intervention for fitness goals, and the one approved myostatin-pathway drug, apitegromab (Isembyld, FDA-approved September 2026), is indicated for spinal muscular atrophy on top of an SMN2-targeted therapy and is given as a 10 mg/kg intravenous infusion every four weeks under specialist care — not for fitness use. Its label also carries a fracture warning, which is worth knowing before treating myostatin blockade as a consequence-free way to add muscle.

Who Myostatin Propeptide Is NOT For

Contraindications
  • •Research peptide with no validated clinical use — not appropriate for self-administration
  • •Patients with diagnosed muscle-wasting conditions should engage with approved or trial-stage myostatin-pathway medicines under clinical care — apitegromab is approved for spinal muscular atrophy, and bimagrumab and others remain investigational — rather than research-channel propeptide
  • •Pregnancy and lactation — no safety data; theoretical TGF-β superfamily disruption concerns
  • •Patients with active cardiovascular disease or vascular pathology — broader TGF-β disruption could theoretically affect vascular biology

Drug & Supplement Interactions

There is no validated human drug-interaction profile. Theoretical interactions follow from the broader myostatin-pathway and TGF-β superfamily class. Concurrent use with antibody-based myostatin antagonists (apitegromab, bimagrumab) or decoy-receptor-based approaches (ACE-031 historical, ActRIIB-Fc fusions) would produce additive myostatin sequestration with unpredictable cumulative effects.

Safety Profile

Safety Information

Common Side Effects

Not characterized in human clinical trials — research peptide with no clinical-development pathwayAnimal studies report no overt toxicity at myostatin-antagonism doses, but tolerability has never been formally characterised for the propeptide in any speciesA documented off-target signal exists: a 2020 Haematologica screen found myostatin propeptide expanded primitive chronic myeloid leukaemia cells, binding the cell surface and increasing STAT5 and SMAD2/3 phosphorylation independently of myostatin

Cautions

  • • Research peptide — no FDA approval for any indication
  • • No validated human dosing regimen, route, or safety basis for self-administration
  • • Theoretical concerns parallel the broader myostatin-antagonism class — TGF-β superfamily disruption could affect tissue homeostasis, fibrosis, and other systems beyond muscle. Bone is no longer theoretical for the class: the approved selective antibody apitegromab carries a fracture warning, and its rat toxicology found femoral-head lesions at every dose tested with no no-effect dose identified
  • • ACE-031 clinical-trial safety signals provide a class-level cautionary reference: the published Duchenne trial was stopped after the second dosing regimen over epistaxis and telangiectasias, consistent with broad TGF-β pathway disruption
  • • Compounded myostatin propeptide in research-chemical channels has no validated clinical use

What We Don't Know

Long-term safety of myostatin propeptide administration is not characterized in humans because no clinical-development pathway has advanced. The class-level myostatin-antagonism safety considerations apply — broader TGF-β superfamily effects, potential vascular and connective tissue effects, theoretical proliferative concerns. Whether the propeptide-based approach produces a different safety profile than antibody-based or decoy-receptor-based myostatin antagonism is not characterized.

Myths & Misconceptions

Myth

Myostatin propeptide is a clinically validated muscle-building therapy.

Reality

It is not. The molecule is research-tier with no FDA approval, no clinical-development pathway, and no validated dosing for fitness or muscle-mass goals. The dominant clinical myostatin-antagonism strategies are antibody-based (apitegromab/SRK-015, FDA-approved for SMA in September 2026 after the Phase 3 SAPPHIRE trial, with a Phase 2 lean-mass-preservation-with-tirzepatide readout in 2026; bimagrumab, still in active Phase 2 development at Eli Lilly; and others) and decoy-receptor-based, not propeptide-based. Anyone considering myostatin propeptide for fitness should engage with the validated foundations (resistance training, protein intake, sleep) rather than research-channel peptides.

Myth

Myostatin propeptide is the same as follistatin.

Reality

They are different proteins with different binding profiles. The myostatin propeptide is myostatin's own N-terminal regulatory domain — it binds mature myostatin specifically. Follistatin is a separate protein that binds and neutralizes multiple TGF-β superfamily ligands including myostatin, activin, and others — broader specificity. Both are endogenous myostatin inhibitors, but mechanistically distinct.

Myth

Buying myostatin propeptide from research-channel vendors gives you a clinical myostatin antagonist.

Reality

It does not. Research-channel myostatin propeptide is not an FDA-approved drug, has no validated clinical-grade manufacturing, and has no human safety database. The clinical myostatin antagonists are antibody-based agents, and one of them is now an approved prescription drug: apitegromab was cleared by the FDA on 11 September 2026 as Isembyld, for spinal muscular atrophy in patients aged two and over already receiving an SMN2-targeted therapy. Others (bimagrumab, GYM329, trevogrumab) remain in trials. None is approved, prescribed or studied for fitness or general muscle-mass goals, and none of them is the propeptide.

Published Research

15 studies

Minimalist d-Tripeptide Prodrug Mimetics of the Myostatin Prodomain as Selective Inhibitors of Skeletal Muscle Atrophy Signaling

PreclinicalPMID: 42865977

Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Meta-AnalysisPMID: 42530342

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial

Pratley, Denham, Trivedi and colleagues, Nature Medicine July 2026. Phase 2 trial of apitegromab as adjunct to tirzepatide-induced weight loss for lean-mass preservation — opens a new GLP-1-adjacent indication that materially reframes the antibody-based myostatin-antagonism landscape from primarily SMA/dystrophy toward the far larger GLP-1/GIP obesity-therapy adjunct market. The most consequential recent shift in the myostatin-antagonism clinical landscape.

Clinical TrialPMID: 42260100

Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives

ReviewPMID: 41954678

Advancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway

ReviewPMID: 41566720

Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial

Crawford, Servais, Mercuri and colleagues, Lancet Neurology September 2025. The Phase 3 SAPPHIRE readout for apitegromab (SRK-015) in non-ambulatory type 2 or type 3 SMA — the most advanced antibody-based myostatin-antagonism trial and the clinical validation of the pro-myostatin-selective antibody strategy that the file previously anticipated as pending. Regardless of headline efficacy magnitude, SAPPHIRE is the landmark clinical evidence for the antibody-based myostatin-antagonism class overall.

Clinical TrialPMID: 40818473

Myostatin Modulation in Spinal Muscular Atrophy: A Systematic Review of Preclinical and Clinical Evidence

Systematic ReviewPMID: 40565321

A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells

Original ResearchPMID: 31582541

Identification of the minimum peptide from mouse myostatin prodomain for human myostatin inhibition

Original ResearchPMID: 25569186

Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice

Original ResearchPMID: 18288893

Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance

Original ResearchPMID: 16182246

Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases

Wolfman, McPherron, Pappano, Davies, Song, Tomkinson, Wright, Zhao, Sebald, Greenspan, and Lee, PNAS 2003. The paper that established how latent myostatin is switched on — BMP-1/tolloid-family metalloproteinases cleave the propeptide and release active myostatin — and showed that a cleavage-resistant mutant propeptide significantly increases muscle mass when injected into adult mice. It is the direct source for this page's activation mechanism and the strongest argument that the propeptide is a drug-like intervention point rather than only a structural curiosity.

Original ResearchPMID: 14671324

Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains

Original ResearchPMID: 12595574

The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum

Hill JJ, Davies MV, Pearson AA, Wang JH, Hewick RM, Wolfman NM, and Qiu Y, Journal of Biological Chemistry 2002. Foundational characterization of the myostatin propeptide and the follistatin-related gene (FSTL3) as the principal inhibitory binding proteins of myostatin in normal serum. Establishes the propeptide-and-latent-complex regulatory framework.

Original ResearchPMID: 12194980

Regulation of myostatin activity and muscle growth

Lee SJ and McPherron AC, Proceedings of the National Academy of Sciences 2001. Often miscatalogued as a review, this is the primary experimental paper behind the propeptide-as-inhibitor idea: transgenic mice expressing the myostatin propeptide, follistatin, or a dominant-negative ActRIIB each showed dramatic increases in muscle mass comparable to myostatin knockouts. It is the strongest animal evidence this page rests on. It also records a caveat the enthusiasm usually drops — the propeptide inhibited myostatin binding to ActRIIB only at higher concentrations than follistatin required.

Original ResearchPMID: 11459935

Myostatin Propeptide Compared

Quick Facts

Class
TGF-Beta Family Inhibitor
Tier
D
Evidence
Preliminary
Safety
Limited Data
Updated
Nov 2026
Citations
15PubMed

Also known as

MSTN propeptideGDF-8 propeptideLatent myostatin

Tags

TGF-Beta FamilyMyostatin InhibitorLatent ComplexResearch Peptide

Related Goals

Evidence Score

Overall Confidence35%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.